Yahoo! Finance: Drugs - Generic Industry News

Salix to File for IBS Indication (Zacks.com)

Wed, 16 Dec 2009 16:52:23 Etc/GMT

Helicos BioSciences Corporation Announces $6.4 Million Registered Direct Offering (Business Wire)

Tue, 15 Dec 2009 22:52:00 Etc/GMT

CAMBRIDGE, Mass.----Helicos BioSciences Corporation announced today that it has priced a registered direct offering of 6.4 million units, at a price of $1.00 per unit, for gross proceeds of $6.4 million before deducting underwriting discounts and commissions and estimated offering expenses.

Cannabis Science Begins National Television Educational Series Today With Traders Nation Airing National Tomorrow On CNN, ABC, Fox, CBS Marketwatch, And CNBC, Focusing On Educating Viewers On The Ground-Breaking Science of Medical Cannabis (Business Wire)

Tue, 15 Dec 2009 19:36:00 Etc/GMT

COLORADO SPRINGS, Colo.----Cannabis Science Inc. , an emerging pharmaceutical cannabis company, is pleased to announce today that it has launched an Educational Series of Television commercials designed to inform its viewers about the importance of groundbreaking cannabis-based medicines.

The Ludwig Institute and Pro-Pharmaceuticals Collaborate to Test DAVANAT®'s Ability to Enhance the Function of Anti-Tumor T Lymphocytes (Business Wire)

Tue, 15 Dec 2009 12:30:00 Etc/GMT

NEWTON, Mass.----Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells.

Large And Small Cap Picks In The Health Care Space: Credit Suisse Analyst Guides Investors On Which Stocks Are A Good Buy (Wall Street Transcript)

Mon, 14 Dec 2009 16:55:00 Etc/GMT

67 WALL STREET, New York - December 14, 2009 - The Wall Street Transcript has just published its Consumer Health Services Report offering a timely review of the sector to serious investors and industry executives. This 53 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy (PR Newswire)

Mon, 14 Dec 2009 13:50:00 Etc/GMT

Watson Pharmaceuticals, Inc. today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy . Nearly two million men are receiving ADT, a palliative treatment for prostate cancer that, while highly effective and considered the "gold therapy," can cause bone loss and increase a man's risk for osteoporosis.

Mylan Added to NASDAQ-100 Index (PR Newswire)

Mon, 14 Dec 2009 13:00:00 Etc/GMT

Mylan Inc. today announced that the company will be added to the NASDAQ-100 Index Dec. 21. Mylan's common shares will also be included in NASDAQ's PowerShares QQQ.

Hi-Tech Pharmacal Co.: Warming Up or Cooling Off? (at Motley Fool)

Fri, 11 Dec 2009 18:48:29 Etc/GMT

Mylan receives another approval for epilepsy drug (AP)

Fri, 11 Dec 2009 13:33:53 Etc/GMT

Generic drugmaker Mylan Inc. said Friday regulators have approved an additional tablet strength for its epilepsy drug Levetiracetam.

Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg (PR Newswire)

Fri, 11 Dec 2009 13:00:00 Etc/GMT

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levetiracetam Tablets, 1000 mg.

Regardless Of U.S. Health Care Legislation Outcome, Senior Analyst Sees Certain PBM Stocks As Strong Performers (Wall Street Transcript)

Thu, 10 Dec 2009 20:18:00 Etc/GMT

67 WALL STREET, New York - December 10, 2009 - The Wall Street Transcript has just published its Consumer Health Services Report offering a timely review of the sector to serious investors and industry executives. This 53 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Equity Valuations In The Health Care Service Space Not To Be Affected By Unemployment Levels, According To BMO Analyst (Wall Street Transcript)

Thu, 10 Dec 2009 20:14:00 Etc/GMT

Pro-Pharmaceuticals Closes $325,000 Tranche (Business Wire)

Thu, 10 Dec 2009 12:30:00 Etc/GMT

NEWTON, Mass.----Pro-Pharmaceuticals, Inc. , today announced that it has closed a $325,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants.

Watson Acquires Arrow (Zacks.com)

Wed, 9 Dec 2009 16:49:55 Etc/GMT

Watson recently completed its acquisition of privately held Arrow Group.

Hi-Tech's 2Q profit surges on generic drugs (AP)

Wed, 9 Dec 2009 16:34:44 Etc/GMT

Hi-Tech Pharmacal Co. said Wednesday its fiscal second-quarter profit surged due to strong sales of generic drugs. Hi-Tech said its profit rose to $7.4 million, or 60 cents per share, for the quarter ended Oct. 31.

Lazard Capital Award Winning Analyst Handicaps Winners And Losers In Stock Market Under New Health Care Legislation (Wall Street Transcript)

Wed, 9 Dec 2009 14:19:00 Etc/GMT

67 WALL STREET, New York - December 9, 2009 - The Wall Street Transcript has just published its Consumer Health Services Report offering a timely review of the sector to serious investors and industry executives. This 53 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Which Health Care Sectors Will Benefit Under Impending Legislation? The Answer According To Lazard Capital (Wall Street Transcript)

Wed, 9 Dec 2009 14:14:00 Etc/GMT

New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO(R) (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief (PR Newswire)

Wed, 9 Dec 2009 13:50:00 Etc/GMT

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® for up to 52 weeks of treatment.

Hi-Tech Pharmacal Reports Sales and Earnings for the Second Fiscal Quarter Ended October 31, 2009 (Business Wire)

Wed, 9 Dec 2009 13:00:00 Etc/GMT

AMITYVILLE, N.Y.----Hi-Tech Pharmacal Co., Inc. today reported results for the quarter ended October 31, 2009.

Hi-Tech Works On First Base Built Above 10 (Investor's Business Daily)

Tue, 8 Dec 2009 23:31:30 Etc/GMT

Microcap company Hi-Tech Pharmacal is shaping its first base above 10.